| abstract |
This invention relates to an industrially feasible process for producing HMG-CoA reductase inhibitor, simvastatin via novel intermediates, wherein the process comprises treating lovastatin [2] or lovastatin ammonium salt [2’] with hydrazine or hydrazine derivatives to obtain lovastatin hydrazide [3], optionally protecting the hydroxyl groups of hydrazide intermediate [3] to obtain protected lovastatin hydrazide intermediate [4] which is further used in the process for producing simvastatin [1]. |